Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- befree-2016 importedOn "2016-02-19" NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion wasGeneratedBy ECO_0000203 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion wasDerivedFrom befree-2016 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion SIO_000772 21898529 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion evidence source_evidence_literature NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.